NCT04210115NCT04210115- **标题 / Title：** Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)Read the abstract →
JJeff Ryckman@jryckman3Score6060KEYNOTE-975: adding pembro to definitive CRT didn't improve EFS in CPS>=10 esophageal/GEJ cancer. HR 0.97 (95% CI 0.77-1.23). Hierarchy stopped there; OS wasn't formally tested. A…Same topic KEYNOTE-975 · 3 peopleHeat 00 likes0 replies0 reposts
OOncoAlert@OncoAlertScore6060OncoAlert 4Sight Abstracts to be Presented at #ESMO26 2875O: Pembrolizumab or Placebo Plus Concurrent Definitive Chemoradiotherapy in Esophageal and Gastroesophageal Junction (GE…Same topic KEYNOTE-975 · 3 people2875OpembrolizumabHeat 2117 likes0 replies4 reposts
DDaisukeKotani@DaisukeKotaniScore6060#ESMO26 | 2875O KEYNOTE-975 Pembro or placebo + dCRT in esophageal cancer - EFS: HR 0.97 (CPS ≥10) - OS: HR 1.00 (CPS ≥10) @myESMO @OncoAlertSame topic KEYNOTE-975 · 3 people2875OHeat 2617 likes0 replies9 reposts
